Résumé
Buspirone is a non-benzodiazepine anxiolytic from the azapirone class that acts primarily on the serotonergic system. Its mechanism of action is based on partial agonism at 5-hydroxytryptamine 1A receptor (5-HT1A) receptors, acting at both presynaptic and postsynaptic sites. It also exhibits moderate antagonism at presynaptic dopamine D2receptors, as well as D3 and D4, contributing to its distinct pharmacological profile.Buspirone was first approved in 1986 by the FDA:Food and Drug Administration (FDA) and has been used to treat anxiety disorders, such as generalized anxiety disorder, and relieve symptoms of anxiety.We describe here a series of five cases of buspirone abuse spontaneously reported to the addictovigilance center of Montpellier since 2023.